Independent Predictors of Bleeding Complications in Patients Undergoing PCI With Concomitant Treatment With Bivalirudin in Clinical Practice Results From the Improver Registry-Reference-Cited by-同舟云学术

Independent Predictors of Bleeding Complications in Patients Undergoing PCI With Concomitant Treatment With Bivalirudin in Clinical Practice Results From the Improver Registry

Published:2013-12 Issue:6 Volume:62 Page:507-511
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:Journal of Cardiovascular Pharmacology

Author:

Koeth Oliver,Gulba Dietrich,Huber Kurt,Madsen Jan Kyst,Darius Harald,Schneider Steffen,Zeymer Uwe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference18 articles.

1. Relation Between Activated Clotting Time During Angioplasty and Abrupt Closure

2. Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina

3. Clinical Applications of Bivalirudin in the Cardiac Catheterization Laboratory

4. Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety

5. Bivalirudin for Patients with Acute Coronary Syndromes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention;The Tohoku Journal of Experimental Medicine;2023

2. A New Preprocedural Score to Predict Bleeding Complications of Endovascular Interventions for Peripheral Artery Disease;Journal of Endovascular Therapy;2019-08-05

3. Differences of bleedings after percutaneous coronary intervention using femoral closure and radial compression devices;Medicine;2019-05

4. Safety of Reversing Anticoagulation by Protamine Following Elective Transfemoral Percutaneous Coronary Intervention in the Drug-Eluting Stent Era;International Heart Journal;2018-05-31